133rd Day Of Lockdown

Maharashtra45795629935616142 Tamil Nadu2682852087844349 Andhra Pradesh176333956251604 Karnataka145830692722704 Delhi1391561252264033 Uttar Pradesh100310572711817 West Bengal80984568841785 Telangana6894649675563 Gujarat65704485612529 Bihar6203140760349 Assam4816233429115 Rajasthan4667932832732 Haryana3779631226448 Odisha3768124483258 Madhya Pradesh3508225414912 Kerala279561629988 Jammu and Kashmir2239614856417 Punjab1901512491462 Jharkhand140705199129 Chhatisgarh10109761369 Uttarakhand8008484795 Goa7075511460 Tripura5520367528 Puducherry4147253758 Manipur301818147 Himachal Pradesh2879171013 Nagaland24056594 Arunachal Pradesh179011053 Chandigarh120671520 Meghalaya9173305 Sikkim7832971 Mizoram5022820
Business Companies 07 Jul 2020 Mylan Pharma to laun ...

Mylan Pharma to launch remdesivir in India at Rs 4,800 per 100 mg vial

ANI
Published Jul 7, 2020, 1:45 pm IST
Updated Jul 7, 2020, 1:45 pm IST
The drug will be launched under the brand name Desrem in India and will be available to patients later this month
Mylan gets DCGI nod for remdesivir in India, to launch at Rs 4,800 per vial. (AFP Photo)
 Mylan gets DCGI nod for remdesivir in India, to launch at Rs 4,800 per vial. (AFP Photo)

Bengaluru: Global pharmaceutical major Mylan has got approval for its remdesivir from the Drug Controller General of India (DCGI) and will launch a generic version of Gilead Sciences' COVID-19 anti-viral in the country at Rs 4,800 for 100 mg/vial.

The drug will be launched under the brand name Desrem in India and will be available to patients later this month at about 80 per cent below the price tag for wealthy nations, the company said.

 

The approval for restricted emergency use is part of the DCGI's accelerated approval process to address urgent, unmet needs amid the evolving coronavirus pandemic.

Mylan will manufacture remdesivir in India at its injectables facilities which also make the product for the United States and have been inspected by the US Food and Drug Administration (FDA) for compliance with good manufacturing practices.

The company said it continues to work extensively toward expanding emergency use access for patients in the 127 low- and middle-income countries where it is licenced by Gilead Sciences to do so, subject to reviews by national regulatory bodies and the pre-qualification programme of the World Health Organisation (WHO).

 

The approval by DCGI in India represents the first for Mylan in these 127 markets.
Mylan President Rajiv Malik said the company and Gilead Sciences have partnered for many years to make high-quality medicines available to people who need them and have made significant progress to reduce the incidence of infectious diseases, including HIV/AIDS, around the world.

"We commend Gilead for their continued leadership on this front, and also applaud and are proud to continue partnering with the DCGI for its ongoing efforts to accelerate access to critical medicine for patients with COVID-19 in India," he said in a statement.

 

Mylan joins domestic pharma firm Cipla and Hetero which have already received permission from the DCGI to manufacture and market remdesivir for the treatment of Covid-19.

In May, domestic pharma firms Hetero, Cipla and Jubilant Life Sciences and pharma major Mylan had entered into non-exclusive licencing agreements with drug major Gilead Sciences Inc for manufacturing and distribution of remdesivir.
The medicine has been issued an emergency use authorisation by the US FDA to treat COVID-19 patients.

...
Location: India, Karnataka, Bengaluru




ADVERTISEMENT
ADVERTISEMENT
ADVERTISEMENT
ADVERTISEMENT
ADVERTISEMENT